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Abstract
The EMRSA-15 clone is a major cause of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK and elsewhere
but existing typing methodologies have limited capacity to discriminate closely related strains, and are often poorly reproducible between
laboratories. Here, we report the design, development and validation of a genome-wide single nucleotide polymorphism (SNP) typing
method and compare it to established methods for typing of EMRSA-15. In order to identify discriminatory SNPs, the genomes of 17
EMRSA-15 strains, selected to represent the breadth of genotypic and phenotypic diversity of EMRSA-15 isolates in Scotland, were
determined and phylogenetic reconstruction was carried out. In addition to 17 phylogenetically informative SNPs, ﬁve binary markers were
included to form the basis of an EMRSA-15 genotyping assay. The SNP-based typing assay was as discriminatory as pulsed-ﬁeld gel
electrophoresis, and signiﬁcantly more discriminatory than staphylococcal protein A (spa) typing for typing of a representative panel of
diverse EMRSA-15 strains, isolates from two EMRSA-15 hospital outbreak investigations, and a panel of bacteraemia isolates obtained in
healthcare facilities in the east of Scotland during a 12-month period. The assay is a rapid, and reproducible approach for epidemiological
analysis of EMRSA-15 clinical isolates in Scotland. Unlike established methods the DNA sequence-based method is ideally suited for
inter-laboratory comparison of identiﬁed genotypes, and its ﬂexibility lends itself to supplementation with additional SNPs or markers for
the identiﬁcation of novel S. aureus strains in other regions of the world.
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Introduction
Healthcare-associated methicillin-resistant Staphylococcus aur-
eus (HA-MRSA) is a cause of signiﬁcant morbidity and
mortality worldwide [1]. The majority of infections are
superﬁcial skin- or upper respiratory tract-associated infec-
tions but approximately 10% of all infections result in
bacteraemias, which have a higher rate of mortality [2–4]. In
the past 20 years, two major clones of HA-MRSA deﬁned by
their pulsed-ﬁeld gel electrophoresis (PFGE) proﬁles have
dominated in the UK; namely epidemic methicillin-resistant
S. aureus 15 (EMRSA-15) and EMRSA-16, corresponding to
sequence type 22 (ST22) and ST36 as determined by
multilocus sequence typing. However, the prevalence of
EMRSA-16 has declined in the UK since 2001 [5,6] and in
2011 the Scottish MRSA Reference Laboratory reported that
EMRSA-15 and EMRSA-16 accounted for 81% and 8%,
respectively, of MRSA infections in Scottish healthcare centres
[7]. The reason(s) for the decline of EMRSA-16 are uncertain
but may be due to overall reduced ﬁtness of EMRSA-16 strains
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resulting from the energy burden of increasing antibiotic
resistance, with a background of improved hygiene for
infection control in hospitals [8].
To date, a variety of molecular methods have been
employed for the typing of MRSA, however, no method has
been developed that provides the requisite discriminatory
ability and convenience criteria for rapid, robust, high-resolu-
tion, portable typing [9]. Recent advances in DNA sequencing
technologies mean that whole genome sequencing of bacteria
is rapid, and increasingly inexpensive, and comparative genome
sequencing of clinical isolates of MRSA has resulted in
important new insights into the emergence and transmission
of epidemic MRSA [8,10–13]. It is anticipated that a whole
genome sequencing approach to investigating outbreaks of
hospital infection will become routine practice within hospital
diagnostic units within the medium-term future. Currently, the
bioinformatic solutions required for user-friendly interpreta-
tion of the sequences are not in place, but genome sequence
analysis could be used to identify single nucleotide polymor-
phisms (SNPs) for the design of routine genotyping assays.
Several typing schemes that exploit genome-wide SNPs have
been developed recently for bacterial pathogens with low
genetic diversity [14–16].
In the current study a whole genome sequencing approach
was employed to identify highly informative SNPs for the
development of a robust, discriminatory and portable multi-
plex allele-speciﬁc primer extension (ASPE) typing assay for
EMRSA-15 strains that may be used to delineate hospital
MRSA outbreaks in Scottish hospitals and to investigate the
association of EMRSA-15 genotypes with disease outcome.
The highly ﬂexible format could be applied to any SNP
identiﬁcation platform, and is easily extendable by the addition
of SNPs to allow identiﬁcation of newly emergent strains.
Materials and Methods
Bacterial strains
To identify discriminatory SNPs for inclusion in the assay, 17
S. aureus strains were chosen for whole genome sequencing.
The strains were selected from the Scottish MRSA Reference
Laboratory database to represent the breadth of genotypic and
phenotypic diversity of EMRSA-15 within Scotland as assessed
by PFGE, antimicrobial susceptibility testing, and toxin gene
detection.
To assess the discriminatory power of the SNP assay four
sets of strains (n = 104) were used. The ﬁrst set comprised 21
diverse epidemiologically unrelated isolates (R1–R24) selected
from the Scottish MRSA Reference Laboratory database,
including the most common PFGE type A1, and strains that
differed from A1 by one band (n = 4; R2, R3, R5, and R24);
two to three bands (n = 9; R6 to R14), four to six bands
(n = 4; R16 to R19), and seven or more bands (n = 3; R21 to
R23) [17]. The second set of isolates (n = 29; R74–R105) were
from an epidemiological investigation involving two geograph-
ically linked but epidemiologically distinct outbreaks, and
several sporadic cases of infection that occurred around the
same time. The ﬁrst outbreak involved neonates at a single
hospital (Hospital B; see Supplementary material, Table S1),
while the second outbreak involved patients with
post-caesarean wound infections at four different hospitals
(Hospitals A, C, D and G) within the same health board as
Hospital B. The third set (n =11) were isolated from eight
patients in March 2009 during enhanced surveillance screening
in a neonatal unit following the detection of MRSA in the nose
of a neonate (R122–R132). The fourth set were bacteraemia
isolates (n = 43) which occurred in the East of Scotland
between September 2010 and September 2011. Cases
occurred in seven healthcare facilities with the majority in
the two largest hospitals (n = 21 and n = 14 isolates, respec-
tively) (R200–R248). All strains were characterized by PFGE
and spa typing and the ﬁrst three sets of isolates had previously
been typed by multilocus variable number tandem repeat
ﬁngerprinting (MLVF) and multilocus variable number tandem
repeat analysis (MLVA) [17]. For detailed strain information
see Supplementary material, Table S1.
DNA extraction
For whole genome sequencing, genomic DNA was isolated
using the Edge Biosystems genomic DNA isolation kit as
previously described [18]. For the SNP assay, DNA was
extracted from isolates using the Qiagen DNeasy Blood and
Tissue Kit as recommended by the manufacturer (Qiagen,
Hilden, Germany).
Next-generation sequencing and SNP identiﬁcation
Sequencing was carried out with the Illumina Genome
Analyser II (Illumina Inc., San Diego,CA, USA) yielding
36-nucleotide paired-end reads that were mapped to the
reference genome sequence of S. aureus strain HO50960412
(Accession number HE681097). SNPs were identiﬁed as
described previously [19], and phylogenetic reconstruction
was carried out using RAXML v7.2.6 for all sites in the core
genome, using a ‘general time reversible’ model of nucleotide
substitution with the c model of rate heterogeneity [20].
Support for nodes was assessed using 1000 bootstrap
replicates. The computer program MINIMUM SNPS v2043 [21]
was used to identify SNP sets with a high Simpson’s index of
diversity (SID) predicted to be discriminatory for EMRSA-15
sublineages. A SNP pseudosequence was contructed for each
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strain, which contained the base calls at each of the locations at
which an SNP was found among the strains. A FASTA ﬁle of the
pseudosequences was imported into MINIMUM SNPS and
analysed using the ‘D’ method. Candidate SNPs were then
screened to determine if they met speciﬁc criteria, including
the condition that regions ﬂanking the SNP were suitable for
primer design and that the SNPs were randomly distributed
throughout the genome.
PCR primer design
Oligonucleotide primers were designed using PRIMER3 software
(http://frodo.wi.mit.edu/primer3). A 301 base-pair (bp) tem-
plate sequence consisting of the SNP base and the 150 bp
ﬂanking regions were entered into the program. The 30 bp
upstream and downstream of the SNP were excluded from
primer selection. The amplicons were designed to be relatively
small (see Supplementary material, Table S2) with similar
melting temperatures to enable efﬁcient ampliﬁcation in
multiplex PCR. Each set of primers was checked to conﬁrm
that they were complementary to all the S. aureus strains using
301-bp sequence alignments in BIOEDIT, and where necessary
degenerate bases were employed. Sequences with secondary
sites of homology of >75% nucleotide identity were excluded,
as were primer pairs with a predicted interaction score >8 as
determined with AUTODIMER [22].
ASPE oligonucleotide design
PRIMERPLEX (Premier Biosoft, Palo Alto, CA, USA) was used to
design the ASPE primers. The parameters used were: primer
Tm 51–56°C, primer length 18–27, primer GC% 20–80%, with
all other parameters as per default settings. Oligonucleotide
primer sequences were selected after screening for predicted
cross-reactions, and secondary annealing sites as for PCR
primer design. The ASPE sequences were tagged with suitable
MagPlex bead-speciﬁc hybridization sequences by Luminex
(Luminex, Austin, TX, USA) and puriﬁed by PAGE (Table S2).
Binary marker selection
Five additional gene targets were chosen for inclusion in the
assay. PCR primers for the genes erm(C), tetK, mecA, mecC
were designed using PRIMER3 as described above. Primers for
the lukS-PV and lukF-PV genes were obtained from Lina et al.
[23]. A single speciﬁc extension primer was designed for each
of the ﬁve binary markers, which were tagged with a MagPlex
bead-speciﬁc hybridization sequence (Luminex) (Table S2).
PCR
Brieﬂy, for each sample, 2 ll of approximately 100 ng genomic
DNA was ampliﬁed in a single-tube 22-plex PCR (Multiplex
PCR Master Mix, Qiagen) containing 0.2 lM of each primer
(Eurogentec, Seraing, Belgium) for 15 min at 95°C, followed by
40 cycles of 94°C (30 s), 55°C (30 s), 72°C (30 s) and 10 min
at 72°C. The amplicons were treated with alkaline phospha-
tase (Invitrogen, Carlsbad, CA, USA) for 90 min to remove the
5′ phosphates of any unincorporated nucleotides, and exonu-
clease I (New England Biolabs, Ipswich, MA, USA) to digest any
unincorporated primers.
ASPE
A 5-ll aliquot of the treated PCR was used in the ASPE
reaction containing 5 lM biotin-labelled d’CTP (Invitrogen)
and 39 primers (0.1 lM) containing sequences speciﬁc for
each allele assayed and a speciﬁc 3′ tag sequence for
subsequent MagPlex bead (Luminex) attachment. The bead
mix contained 39 different bead types, each with a unique
ﬂuorescent signature for bead identiﬁcation and an oligonu-
cleotide tag for speciﬁc ASPE product hybridization. The ASPE
products were hybridized to the Bead Mix (96°C for 30 s
followed by 30 min at 37°C) and products were incubated
with streptavidin-conjugated R-phycoerythrin (Invitrogen)
reporter dye. Samples were read on the Luminex xMAPTM
system (Luminex 200 instrument), and signal was generated
for each of the 17 SNP mutations and their corresponding
wild-type alleles in addition to the ﬁve binary markers. For
each strain, the net mean ﬂuorescent intensity (MFI) values
were analysed to determine the presence of wild-type or
mutant alleles and, in the case of the binary markers, gene
presence or absence.
Comparison with other typing assays and clustering analysis
PFGE [16] and staphylococcal protein A (spa) typing [24] analysis
were performed as described previously. The SIDwas calculated
using the online tool COMPARING PARTITIONS (www.darwin.
phyloviz.net/ComparingPartitions/). The distance between
SNP types was calculated using the R dist function with the
binary distance measure in the program R (http://www.R-project.
org/). Clustering was performed using the HCLUST function, with
distances between clusters calculated using Ward’s minimum
variancemethod.Height refers to the distance betweenclusters as
calculated by Ward’s minimum variance method.
Antibiograms
Antibiograms were determined using a Vitek GPS-528 card
(customized Staphylococcus card; BioMerieux, Marcy l’Etoile,
France).
Repeatability and reproducibility
The intra-assay variability (repeatability) was assessed by
calculating the co-efﬁcient of variation (Cv) of the MFI values
for three repeats of 12 strains in one run.
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Results and Discussion
Design and development of the SNP-based typing assay
To identify discriminatory SNPs for inclusion in the assay, 17
S. aureus strains, representing the breadth of genotypic and
phenotypic diversity of EMRSA-15 within Scotland, were
selected for whole genome sequencing. A total of 904
high-quality SNPs were identiﬁed in the core genome of the
strains, including 723 strain-speciﬁc (detected in only one of
the 17 strains) and 181 present in two or more strains. The
majority of the strain-speciﬁc SNPs were identiﬁed in three
highly divergent strains (07.2384, 07.5739, 08.5828) indicating
extensive intra-clonal genetic diversity within the PFGE-de-
ﬁned EMRSA-15 lineage (Fig. 1). As described in the Materials
and Methods section, discriminatory SNPs were identiﬁed
using the programme MINIMUM SNPs, which has previously
been used to identify a panel of SNPs from multilocus
sequence typing sequence data that distinguishes S. aureus
into groups consistent with the population structure [25]. In
total, a set of 17 SNPs predicted to be discriminatory for the
EMRSA-15 subtypes were selected for the assay (Table S2).
Five binary markers were also included based on their
potential for subdividing the EMRSA-15 subtypes, including the
antibiotic-resistance determinants ermC, tetK, mecA and mecC
and the virulence determinant lukS/lukF-PV. In addition to
increasing the discriminatory power of the assay the diagnostic
utility of molecular determination of antibiotic resistance was
recently demonstrated by Holden et al.[13] who assigned a
molecular basis to 99.8% of the antibiotic resistance of
EMRSA-15. Although the assay was applied to the Luminex
xMAPTM platform, it could easily be adapted to any system with
the capacity for SNP identiﬁcation, demonstrating its inherent
ﬂexibility.
The EMRSA-15 SNP-based assay is as discriminatory as PFGE
for the resolution of EMRSA-15 infection outbreaks
The superior ability of bacterial SNP-based typing assays to
inform on the existence of locally endemic clones of MRSA
was previously demonstrated by N€ubel et al. [26] who
employed a novel SNP-based assay to demonstrate the
existence of a hospital-associated ST225 clone in a German
hospital. To compare the discriminatory ability of the assay
designed here with the established typing methods of PFGE
PFGE type
PF15a
PF15-91/PF15-260/PF15-324
PF15t/PF15-476
PF15-34/PF15-115/PF15-124/PF15-132
PF15a
PF15-216
PF15a/PF15-559
PF15-118
PF15-185
PF15b/PF15z/PF15-71
PF15h/PF15-133/PF15-427
PF15-55
PF15-46/PF15-75
PF15-314/PF15-315
PF15-59
PF15a
PF15a/PF15-48/PF15-68/PF15-178
Strain 
FIG. 1. Phylogenetic reconstruction of 17 EMRSA-15 strains selected to represent the diversity of EMRSA-15 in Scotland over time and space. A
maximum likelihood tree was constructed based on all sites in the core genome, using a ‘general time reversible’ model of nucleotide substitution
with the c model of rate heterogeneity. Pulsed-ﬁeld gel electrophoresis type of each isolate is indicated. Support for nodes was assessed using 1000
bootstrap replicates.
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and spA typing, a total of 104 EMRSA-15 strains representing
four different sets of isolates, as described in the Materials and
Methods, were employed (Table S1). Importantly, for the total
of 104 isolates from all four groups, the SNP assay was equally
as discriminatory as the current reference standard, PFGE
(SID = 0.91, 95% CI 0.89–0.94 compared with SID = 0.90,
95% CI 0.85–0.94 for SNP typing and PFGE, respectively), and
had an overall signiﬁcantly greater capacity to distinguish
EMRSA-15 variants than spa typing (SID = 0.71, 95% CI 0.62–
0.80) (Table 1). In addition, for the ﬁrst three sets of isolates,
which had been typed previously by MLVA and MLVF, the SNP
assay had an overall index of diversity comparable to MLVF and
a signiﬁcantly greater capacity to distinguish EMRSA-15
variants than MLVA (Table 1). For the mixed neonatal/
post-caesarean wound infection panel the SNP assay was able
to discriminate among 29 isolates that were indistinguishable
by PFGE. In particular, strains could be linked to two distinct
outbreaks (R76, R102, R103, R104, R105 in hospital B and R74,
R83, R84, R87, R88, R89, R90, R91, R92, R95, R96, R99, R100
in hospitals A, C, D and G within the same health board)
(Fig. 2; Table S1). Furthermore, the latter outbreak was caused
by a genotype also found colonizing an epidemiologically linked
surgeon (R74), identifying a potential vehicle of transmission
between hospitals, and outbreak isolates were distinguished
from other temporally and geographically related isolates (R75,
R78, R79, R80, R81, R82, R85, R86, R94, R98). One isolate
from hospital B (R77) clustered with the outbreak associated
with hospitals A, C, D and G, which was suggestive of an
inter-hospital transmission event or loss of the erythromycin-
resistance marker. In the case of the neonatal outbreak panel
(n = 11), PFGE and SNP typing identiﬁed neonate isolates (R123,
R125, R126, R127, R131 and R132) that were indistinguishable
from an environmental contaminant of the neonatal unit (R129),
but were distinct from isolates colonizing several other neonates
(R122, R124, R128 and R130).
Although the total number of genotypes identiﬁed by the
SNP assay is less than that of PFGE (24 types compared with
41 types, respectively, for the 104 isolates), the comparable
SID values indicate that the SNP assay is less likely to exhibit
the predominance of one genotype (a problematic feature of
some other molecular typing methods) (Table 1). spA typing
has previously been shown to be unsuitable for distinguishing
closely related EMRSA-15 isolates [27]. Similarly, in the
current analysis, a single spa type, t032, accounted for 51.9%
(54/104) of the MRSA isolates compared with the predominant
SNP types, s850 and s872, which were responsible for 16.4%
(17/104) and 10.6% (11/104) of isolates, respectively. The
greater discriminatory ability is presumably the result of the
genome-wide approach to design of the assay, leading to the
identiﬁcation of SNPs that capture a greater proportion of the
genomic variation of the EMRSA-15 lineage. It should be
pointed out that isolates, R123, R125, R126, R127, R131 and
R132 from the neonatal outbreak were indistinguishable by
SNP typing from isolates from a different hospital (R102, R103,
R104, R105) that had a distinct spA and PFGE type (Fig. 2;
Table S1). However, within each hospital, the SNP-typing
assay was effective in differentiating outbreak and sporadic
isolates. The SNP assay can be performed more rapidly than
PFGE (within 2 days), and compares favourably in cost
(approximately €12 per isolate). Overall, the application of
the SNP-based assay to four well-deﬁned panels of EMRSA-15
isolates revealed a rapid, robust, reproducible (intra-assay Cv
<25%), and discriminatory technique that could be used to
trace outbreaks in Scottish hospitals.
Concluding comments
The predominance of a small number of hospital clones of
MRSA of limited heterogeneity often precludes the successful
delineation of outbreaks using established typing methods. An
effective typing scheme is an essential prerequisite for
TABLE 1. Simpson’s index of diversity (SID) analysis of the SNP assay on four different panels of EMRSA-15 isolates in
comparison to established typing methods
Group
(n = no. of isolates)
PFGE Spa SNP MLVF MLVA
No. of
types SID (95% CI)
No. of
types SID (95% CI)
No. of
types SID (95% CI)
No. of
types SID (95% CI)
No. of
types SID (95% CI)
Diverse PFGE
group (n = 21)
21 1.00 (1.00–1.00) 6 0.55 (0.31–0.79) 11 0.91 (0.84–0.98) 14 0.90 (0.78–1.00) 10 0.73 (0.53–0.94)
PCWI outbreak
investigation (n = 29)
1 0.00 (0.00–0.00) 5 0.73 (0.62–0.84) 6 0.73 (0.59–0.87) 7 0.75 (0.63–0.88) 6 0.55 (0.36–0.75)
Neonatal
outbreak (n = 11)
5 0.60 (0.31–0.89) 2 0.60 (0.31–0.89) 4 0.60 (0.31–0.89) 3 0.47 (0.16–0.78) 4 0.60 (0.31–0.89)
Bacteraemia
isolates (n = 43)
22 0.94 (0.90 – 0.98) 13 0.65 (0.49–0.80) 19 0.91 (0.86–0.96) ND ND
Total 41 0.90 (0.85–0.94) 19 0.71 (0.62–0.80) 24 0.91 (0.89–0.94) 23 0.89 (0.84–0.94) 16 0.63 (0.49–0.77)
MLVA, multilocus variable number tandem repeat analysis; MLVF, multilocus variable number tandem repeat ﬁngerprinting; ND, not done; PCWI, post-caesarean wound infection;
PFGE, pulsed-ﬁeld gel electrophoresis; SNP, single nucleotide polymorphism.
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investigation of MRSA population structure on local, national
and international levels. In future, the ability to rapidly
sequence whole bacterial genomes will supplant many tradi-
tional typing methodologies for frontline epidemiological
investigation of outbreaks but the resources and bioinformatic
solutions are not in place yet for routine use [19,28–30]. The
(a)
(c)
(b)
FIG. 2. Single nucleotide polymorphism-based clustering analysis of EMRSA-15 isolates. Clustering analysis of isolates from (a) two
epidemiologically distinct outbreaks from the same health board, and several concomitant sporadic cases of infection. Isolates (blue branches)
were obtained from neonates at a single hospital (b) (Table S1), and the second outbreak (green branches) involved patients with post-caesarean
wound infections at four different hospitals (Hospitals A, C, D and G) within the same health board as Hospital B. (b) Eleven isolates from eight
patients in a neonatal unit (R122–R132) revealing several related isolates (red branches) distinguishable from other isolates obtained in the same unit
at the same time. Height refers to the distance between clusters as calculated by Ward’s minimum variance method. (c) Clustering analysis of all 104
isolates examined in the current study with outbreak-associated isolates colour-coded as previously described.
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whole genome SNP-based approach described here has
advantages over current typing methodologies based on
discriminatory indices, portability, adaptability and cost. In
particular, the assay can potentially be applied to any
SNP-identiﬁcation platform, and is easily extended to include
SNPs and other genetic markers that capture strains which are
newly emergent, or predominant in different geographic
regions.
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